Document is current
Any future updates will be listed below
-
Authors
Asowed, Mustafa
Elander, Nils O
Pettersson, Linn
Ekholm, Maria
Papantoniou, Dimitrios
-
Funding
Funding for this research was provided by:
Uppsala University
- License Information
-
More Information
Article History
Received: 30 October 2022
Accepted: 27 March 2023
First Online: 4 April 2023
Declarations
:
: ME: Advisory board: Pfizer, Novartis; Lecture fees: AstraZeneca, all outside the submitted work. DP: Advisory board: MSD; Lecture fees: Ipsen, all outside the submitted work. MA, NOE and LP declare that they have no potential conflicts of interest.
: This study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Linköping ethical review board (diary number 2018/139 − 31).
: Due to the retrospective non-interventional design and the fact that the vast majority of patients were not alive at time of data collection, the Linköping ethical review board (diary number 2018/139 − 31) waived the need for informed consent.
: Not applicable.
